Clinical Trials in Binzhou, China
5 recruiting
Showing 1–14 of 14 trials
Recruiting
Phase 3
Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
Severe Asthma
AstraZeneca400 enrolled75 locationsNCT07363642
Recruiting
Phase 1
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
MelanomaNon-small Cell Lung CancerRenal Cell Carcinoma
Shanghai Henlius Biotech174 enrolled69 locationsNCT07160335
Recruiting
Phase 2
Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)
Ulcerative Colitis
InSilico Medicine Hong Kong Limited80 enrolled24 locationsNCT07265570
Recruiting
This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab
Chronic Obstructive Pulmonary Disease
AstraZeneca1,000 enrolled16 locationsNCT06862206
Recruiting
Phase 3
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines150 enrolled64 locationsNCT06970743
Recruiting
Phase 3
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
Locally Advanced or Metastatic Breast Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.460 enrolled60 locationsNCT06680921
Recruiting
Phase 2
A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
Non-small Cell Lung Cancer
RemeGen Co., Ltd.80 enrolled34 locationsNCT06962865
Recruiting
Phase 3
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
AstraZeneca5,500 enrolled794 locationsNCT05952557
Recruiting
Phase 1Phase 2
Study of XNW28012 in Subjects with Advanced Solid Tumors Who Failed Standard Treatments
Ovarian CancerPancreatic CarcinomaAdvanced Solid Tumors+1 more
Evopoint Biosciences Inc.200 enrolled24 locationsNCT06799637
Recruiting
Phase 2
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
Metastatic Gastric CancerUnresectable Gastric CarcinomaHER2-positive Gastric Cancer
Qilu Hospital of Shandong University110 enrolled20 locationsNCT06730373
Recruiting
Phase 3
Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.
Non-small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.518 enrolled71 locationsNCT05922345
Recruiting
Phase 3
PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer
SCLC
Biotheus Inc.404 enrolled45 locationsNCT06616532
Recruiting
A Research Protocol for Evaluating the Efficacy of Perfused Chemotherapeutic Agents for Bladder Cancer Based on Organoid Technology
Bladder Cancer
Qilu Hospital of Shandong University293 enrolled17 locationsNCT06662071
Recruiting
Phase 3
Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
Hepatocellular Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.480 enrolled67 locationsNCT05862337